Search alternatives:
026 decrease » _ decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
026 decrease » _ decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
801
Vasopressin decreases EPSPs in CA2 after LTP induction.
Published 2013“…Values are expressed as % of the mean of the responses recorded during 5 min before AVP application. …”
-
802
SPL decreases diabetes-induced oxidative stress in GL and PT.
Published 2017“…Similar results were found between CTL and SPL groups. Data are mean±SEM from 5–6 rats per group. *p<0.05; **p<0.01 and ***p<0.001.…”
-
803
-
804
-
805
-
806
-
807
-
808
The expression of genes related to mitochondria was decreased in Pgam2 mice.
Published 2013“…NRF-1: nuclear respiratory factor 1; CD36/FAT: CD36/fatty acid translocase; MCAD: medium-chain acyl coenzyme A dehydrogenase; Cox5a: mitochondrial cytochrome c oxidase subunit Va. …”
-
809
-
810
-
811
-
812
-
813
-
814
-
815
-
816
-
817
PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis
Published 2016“…<p><b><i>Background:</i></b> Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and treatment options are limited. …”
-
818
Acute JMV2959 treatment decreases alcohol preference in rats.
Published 2013“…<p>(A) Acute administration of the GHS-R1A antagonist JMV2959 (1 or 3 mg/kg) decreases the alcohol preference compared to vehicle at 1 hour time interval in rats voluntarily consuming alcohol for two and five months before the treatment. …”
-
819
-
820
Acute JMV2959 treatment decreases alcohol intake in rats.
Published 2013“…<p>(A) The acute effects of the GHS-R1A antagonist JMV2959 (1 or 3 mg/kg) administration on alcohol intake was evaluated at 1 hour time interval after both two and five months of voluntary alcohol consumption. …”